Publications by authors named "W C Huskins"
Article Synopsis
- * A 16-year-old girl with Hodgkin's lymphoma developed a vesicular rash after completing chemotherapy, which was identified as a disseminated rash caused by the Oka vaccine-strain varicella-zoster virus, 11 years after her last vaccination.
- * This case emphasizes the importance of understanding potential complications of immunizations, particularly in patients who become immunocompromised later in life, and highlights the necessity of viral genotyping to differentiate vaccine strains from wild-type infections.*
Background: Use of anti-carbapenem-resistant Enterobacterales (anti-CRE) agents such as ceftazidime/avibactam has been associated with improved clinical outcome in cohorts that primarily include patients infected with CRE that are resistant to meropenem (MCRE).
Objectives: To clarify whether patients with CRE resistant to ertapenem but susceptible to meropenem (ertapenem-only-resistant Enterobacterales; EORE) benefit from therapy with anti-CRE agents.
Methods: Patients treated for CRE infection in hospitals in the USA between 2016 and 2019 and enrolled in the CRACKLE-2 study were included.
Importance: Pediatric consensus guidelines recommend antibiotic administration within 1 hour for septic shock and within 3 hours for sepsis without shock. Limited studies exist identifying a specific time past which delays in antibiotic administration are associated with worse outcomes.
Objective: To determine a time point for antibiotic administration that is associated with increased risk of mortality among pediatric patients with sepsis.
Background: Carbapenem-resistant (CRE) are an urgent public health threat in the United States.
Objective: Describe the clinical and molecular epidemiology of CRE in a multicenter pediatric cohort.
Methods: CRACKLE-1 and CRACKLE-2 are prospective cohort studies with consecutive enrollment of hospitalized patients with CRE infection or colonization between 24 December 2011 and 31 August 2017.
Background: Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy.
View Article and Find Full Text PDF